Catalent Pharma Solutions (booth 1546), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, has announced that it has won the ‘Editor’s Choice’ category at the annual INTERPHEX Awards, for its OptiForm Solution Suite platform.
OptiForm Solution Suite is an integrated, fixed price service, designed to efficiently and rapidly help solve complex bioavailability challenges for early stage molecules, using a unique toolkit of bioavailability enhancing technologies, including comprehensive molecule characterization and unique salt screening assessment combined with parallel processing up to four superior formulation technologies.
The OptiForm Solution Suite matches the best formulation technologies to the molecule and utilizes an accelerated parallel screening and development approach, based on rigorous science and best-in-class scientific expertise, in just 12 weeks.
“In the early stages of drug development, it is vital to achieve a suitable formulation so that animal pharmacokinetic studies can be initiated quickly,” commented Julien Meissonnier, Vice President, Science & Technology. “The combination of a wide array of innovative formulation technology options, and rapid screening and selection techniques available through the OptiForm Solution Suite can help overcome these challenges.”
Catalent’s OptiForm Solution Suite platform was presented at the INTERPHEX opening ceremony, on Tuesday 26 April. The convention is currently taking place at The Javits Center, New York City, and runs until Thursday 28 April.